Replimune Group Ownership | Who Owns Replimune Group?
Replimune Group Ownership Summary
Replimune Group is owned by 88.55% institutional investors, 4.74% insiders, and 6.72% retail investors. Baker bros. advisors lp is the largest institutional shareholder, holding 15.09% of REPL shares. US Small-Cap Growth II Equity Comp is the top mutual fund, with 6.43% of its assets in Replimune Group shares.
REPL Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Replimune Group | 88.55% | 4.74% | 6.72% |
| Sector | Healthcare Stocks | 49.73% | 8.84% | 41.43% |
| Industry | Biotech Stocks | 47.04% | 8.74% | 44.21% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Baker bros. advisors lp | 10.05M | 15.09% | $90.41M |
| Price t rowe associates inc /md/ | 9.24M | 13.87% | $83.13M |
| Redmile group | 5.56M | 8.36% | $50.06M |
| Fcpm iii services b.v. | 4.87M | 7.31% | $43.80M |
| Blackrock | 4.71M | 7.08% | $42.42M |
| Millennium management | 3.12M | 4.68% | $28.06M |
| Vanguard group | 2.90M | 4.35% | $26.06M |
| Omega fund management | 2.46M | 3.70% | $22.15M |
| Morgan stanley | 1.74M | 2.61% | $15.62M |
| Boxer capital | 1.54M | 2.31% | $13.83M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Omega fund management | 2.46M | 16.41% | $22.15M |
| Fcpm iii services b.v. | 4.87M | 6.46% | $43.80M |
| Redmile group | 5.56M | 3.03% | $50.06M |
| Nan fung group | 204.94K | 1.97% | $1.84M |
| Ghost tree capital | 450.00K | 1.27% | $4.05M |
| Baker bros. advisors lp | 10.05M | 1.16% | $90.41M |
| Tang capital management | 805.44K | 0.74% | $7.25M |
| Boxer capital | 1.54M | 0.73% | $13.83M |
| Parkman healthcare partners | 525.00K | 0.63% | $4.72M |
| Braidwell lp | 1.01M | 0.29% | $9.12M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Price t rowe associates inc /md/ | 9.24M | 0.01% | 2.69M |
| Millennium management | 3.12M | 0.01% | 2.66M |
| Redmile group | 5.56M | 3.03% | 1.83M |
| Boxer capital | 1.54M | 0.73% | 1.54M |
| Rtw investments, lp | 1.13M | 0.16% | 1.13M |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| State street | 1.16M | 0.00% | -5.33M |
| Atlas venture life science advisors | - | - | -2.10M |
| Camber capital management lp | - | - | -1.35M |
| Jefferies financial group | - | - | -1.00M |
| Morgan stanley | 1.74M | 0.00% | -918.38K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Boxer capital | 1.54M | 0.73% | 1.54M | $13.83M |
| Rtw investments, lp | 1.13M | 0.16% | 1.13M | $10.20M |
| Braidwell lp | 1.01M | 0.29% | 1.01M | $9.12M |
| Ecor1 capital | 850.34K | 0.23% | 850.34K | $7.65M |
| Tang capital management | 805.44K | 0.74% | 805.44K | $7.25M |
Sold Out
| Holder | Change |
|---|---|
| Nelson, van denburg & campbell wealth management group | -8.00 |
| Global retirement partners | -32.00 |
| Riggs asset managment | -58.00 |
| Truvestments capital | -80.00 |
| Private trust co na | -83.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2024 | 147 | -2.65% | 69,570,682 | -1.86% | 88 | 0.84% | 80 | -8.05% | 39 | -17.02% |
| Jun 30, 2024 | 150 | -2.60% | 70,892,178 | 6.49% | 106 | 1.07% | 86 | 3.61% | 47 | 20.51% |
| Mar 31, 2024 | 154 | 4.76% | 66,572,511 | 0.83% | 99 | 1.02% | 83 | -10.75% | 39 | 21.88% |
| Dec 31, 2023 | 147 | 0.68% | 66,021,205 | 16.25% | 99 | 1.35% | 93 | 38.81% | 32 | -21.95% |
| Sep 30, 2023 | 146 | -0.68% | 56,794,193 | 4.05% | 85 | 0.97% | 67 | 1.52% | 41 | -30.51% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| US Small-Cap Growth II Equity Comp | 4.39M | 6.43% | -15.52K |
| T. Rowe Price New Horizons | 4.39M | 6.43% | -13.84K |
| Vanguard Total Stock Mkt Idx Inv | 1.84M | 2.69% | -186.26K |
| iShares Russell 2000 ETF | 1.56M | 2.29% | -3.51K |
| T. Rowe Price Health Sciences | 1.49M | 2.18% | -29.74K |
| T. Rowe Price Integrated US Sm Gr Eq | 1.34M | 1.96% | -34.33K |
| T. Rowe Price Integrated US SmCapGrEq | 1.34M | 1.96% | 766.00K |
| SPDR® S&P Biotech ETF | 1.12M | 1.63% | 12.34K |
| T. Rowe Price New Horizons Tr-Z | 1.00M | 1.47% | 162.79K |
| Vanguard Institutional Extnd Mkt Idx Tr | 860.21K | 1.26% | -3.01K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Dec 16, 2024 | Patel Sushil | Chief Executive Officer | Sell | $124.20K |
| Nov 18, 2024 | Xynos Konstantinos | Chief Medical Officer | Sell | $78.11K |
| Nov 18, 2024 | Sarchi Christopher | Chief Commercial Officer | Sell | $56.13K |
| Aug 16, 2024 | Hill Emily Luisa | Chief Financial Officer | Sell | $90.99K |
| Jun 07, 2024 | Xynos Konstantinos | Chief Medical Officer | Sell | $119.11K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2024 Q4 | - | 3 |
| 2024 Q3 | - | 1 |
| 2024 Q2 | - | 8 |
| 2023 Q4 | - | 2 |
| 2023 Q3 | - | 6 |
REPL Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools